WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H527714
CAS#: 875685-46-4
Description: CXA-10, also known as 10-Nitrooleic acid, is an endogenous nitro-fatty acid (NFA) modulator of Nrf2 and NF-κB potentially for the treatment of acute kidney injury and renal failure. CXA-10 upregulated expression of caveolin-1, the major structural component of caveolae. CXA-10 significantly attenuated increases in plasma cholesterol, heart weight, and kidney weight observed in the model without impacting systemic arterial blood pressure. CXA-10 also reduced albuminuria, nephrinuria, glomerular hypertrophy, and glomerulosclerosis in the model, At the appropriate dose, the nitrated fatty acid CXA-10 exhibits anti-inflammatory and antifibrotic effects in the kidney and limits renal injury in a model of CKD.
Hodoodo Cat#: H527714
Name: CXA-10
CAS#: 875685-46-4
Chemical Formula: C18H33NO4
Exact Mass: 327.24
Molecular Weight: 327.470
Elemental Analysis: C, 66.02; H, 10.16; N, 4.28; O, 19.54
Synonym: CXA-10; CXA 10; CXA10; 10-Nitrooleic acid; 10-nitro-9(E)-octadec-9-enoic acid;
IUPAC/Chemical Name: (E)-10-nitrooctadec-9-enoic acid
InChi Key: WRADPCFZZWXOTI-BMRADRMJSA-N
InChi Code: InChI=1S/C18H33NO4/c1-2-3-4-5-8-11-14-17(19(22)23)15-12-9-6-7-10-13-16-18(20)21/h15H,2-14,16H2,1H3,(H,20,21)/b17-15+
SMILES Code: CCCCCCCC/C([N+]([O-])=O)=C\CCCCCCCC(O)=O
Appearance: liquid
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in ethanol
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in ethanol
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 327.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Perecko T, Hoferova Z, Hofer M, Pereckova J, Falk M. Administration of nitro- oleic acid mitigates radiation-induced hematopoietic injury in mice. Life Sci. 2022 Dec 1;310:121106. doi: 10.1016/j.lfs.2022.121106. Epub 2022 Oct 20. PMID: 36272465.
2: Medrek S, Melendres-Groves L. Evolving nonvasodilator treatment options for pulmonary arterial hypertension. Curr Opin Pulm Med. 2022 Sep 1;28(5):361-368. doi: 10.1097/MCP.0000000000000887. Epub 2022 Jul 16. PMID: 35838352.
3: Hernychova L, Alexandri E, Tzakos AG, Zatloukalová M, Primikyri A, Gerothanassis IP, Uhrik L, Šebela M, Kopečný D, Jedinák L, Vacek J. Serum albumin as a primary non-covalent binding protein for nitro-oleic acid. Int J Biol Macromol. 2022 Apr 1;203:116-129. doi: 10.1016/j.ijbiomac.2022.01.050. Epub 2022 Jan 19. PMID: 35063491.
4: Pereckova J, Pekarova M, Szamecova N, Hoferova Z, Kamarytova K, Falk M, Perecko T. Nitro-Oleic Acid Inhibits Stemness Maintenance and Enhances Neural Differentiation of Mouse Embryonic Stem Cells via STAT3 Signaling. Int J Mol Sci. 2021 Sep 15;22(18):9981. doi: 10.3390/ijms22189981. PMID: 34576143; PMCID: PMC8468660.
5: Zhou C, Su M, Sun P, Tang X, Yin KJ. Nitro-oleic acid-mediated blood-brain barrier protection reduces ischemic brain injury. Exp Neurol. 2021 Dec;346:113861. doi: 10.1016/j.expneurol.2021.113861. Epub 2021 Sep 7. PMID: 34499902.
6: Manni ML, Heinrich VA, Buchan GJ, O'Brien JP, Uvalle C, Cechova V, Koudelka A, Ukani D, Rawas-Qalaji M, Oury TD, Hart R, Ellgass M, Mullett SJ, Fajt ML, Wenzel SE, Holguin F, Freeman BA, Wendell SG. Nitroalkene fatty acids modulate bile acid metabolism and lung function in obese asthma. Sci Rep. 2021 Sep 7;11(1):17788. doi: 10.1038/s41598-021-96471-9. PMID: 34493738; PMCID: PMC8423735.
7: Braumann S, Schumacher W, Im NG, Nettersheim FS, Mehrkens D, Bokredenghel S, Hof A, Nies RJ, Adler C, Winkels H, Knöll R, Freeman BA, Rudolph V, Klinke A, Adam M, Baldus S, Mollenhauer M, Geißen S. Nitro-Oleic Acid (NO2-OA) Improves Systolic Function in Dilated Cardiomyopathy by Attenuating Myocardial Fibrosis. Int J Mol Sci. 2021 Aug 22;22(16):9052. doi: 10.3390/ijms22169052. PMID: 34445757; PMCID: PMC8396484.
8: Nettersheim FS, Lemties J, Braumann S, Geißen S, Bokredenghel S, Nies R, Hof A, Winkels H, Freeman BA, Klinke A, Rudolph V, Baldus S, Mehrkens D, Mollenhauer M, Adam M. Nitro-oleic acid reduces thoracic aortic aneurysm progression in a mouse model of Marfan syndrome. Cardiovasc Res. 2022 Jul 20;118(9):2211-2225. doi: 10.1093/cvr/cvab256. PMID: 34324651.
9: Mollenhauer M, Mehrkens D, Klinke A, Lange M, Remane L, Friedrichs K, Braumann S, Geißen S, Simsekyilmaz S, Nettersheim FS, Lee S, Peinkofer G, Geisler AC, Geis B, Schwoerer AP, Carrier L, Freeman BA, Dewenter M, Luo X, El- Armouche A, Wagner M, Adam M, Baldus S, Rudolph V. Nitro-fatty acids suppress ischemic ventricular arrhythmias by preserving calcium homeostasis. Sci Rep. 2020 Sep 18;10(1):15319. doi: 10.1038/s41598-020-71870-6. PMID: 32948795; PMCID: PMC7501300.
10: Zhao Y, Chang Z, Zhao G, Lu H, Xiong W, Liang W, Wang H, Villacorta L, Garcia-Barrio MT, Zhu T, Guo Y, Fan Y, Chang L, Schopfer FJ, Freeman BA, Zhang J, Chen YE. Suppression of Vascular Macrophage Activation by Nitro-Oleic Acid and its Implication for Abdominal Aortic Aneurysm Therapy. Cardiovasc Drugs Ther. 2021 Oct;35(5):939-951. doi: 10.1007/s10557-020-07031-8. Epub 2020 Jul 15. PMID: 32671602; PMCID: PMC7855321.
11: Garner RM, Mould DR, Chieffo C, Jorkasky DK. Pharmacokinetic and Pharmacodynamic Effects of Oral CXA-10, a Nitro Fatty Acid, After Single and Multiple Ascending Doses in Healthy and Obese Subjects. Clin Transl Sci. 2019 Nov;12(6):667-676. doi: 10.1111/cts.12672. Epub 2019 Aug 12. PMID: 31343124; PMCID: PMC6853153.
12: Arbeeny CM, Ling H, Smith MM, O'Brien S, Wawersik S, Ledbetter SR, McAlexander A, Schopfer FJ, Willette RN, Jorkasky DK. CXA-10, a Nitrated Fatty Acid, Is Renoprotective in Deoxycorticosterone Acetate-Salt Nephropathy. J Pharmacol Exp Ther. 2019 Jun;369(3):503-510. doi: 10.1124/jpet.118.254755. Epub 2019 Mar 20. PMID: 30894457.
13: Schopfer FJ, Vitturi DA, Jorkasky DK, Freeman BA. Nitro-fatty acids: New drug candidates for chronic inflammatory and fibrotic diseases. Nitric Oxide. 2018 Sep 1;79:31-37. doi: 10.1016/j.niox.2018.06.006. Epub 2018 Jun 23. PMID: 29944935; PMCID: PMC6280193.
